Harrow licenses 5 ophthalmic products to Canada-based Apotex
Click Here to Manage Email Alerts
Harrow has announced an exclusive out-licensing agreement with Apotex, a major Canadian pharmaceutical company, to market and distribute five of the company’s branded ophthalmic products.
“We are pleased to enter the Canadian market through this partnership with Apotex, which has a proven track record of success serving Canadian eye care professionals and their patients,” Mark L. Baum, Harrow chairman and CEO, said in a company press release. “This exclusive agreement fulfills our commitment to access and availability of these five important ophthalmic pharmaceutical products.”
According to the release, the agreement grants Apotex exclusive rights and marketing authorizations to Verkazia (cyclosporine ophthalmic emulsion 0.1%), a calcineurin inhibitor immunosuppressant to treat vernal keratoconjunctivitis in children aged 4 years through adolescence, and Cationorm Plus, an over-the-counter, preservative-free emulsion to treat symptoms of dry eye disease and signs and symptoms of ocular allergy.
In addition, Apotex will pursue approval in Canada for Vevye (cyclosporine ophthalmic solution 0.1%), a water-free, perfluorobutylpentane-based product for dry eye disease; Iheezo (chloroprocaine hydrochloride ophthalmic gel 3%), a single-use low-viscosity gel for ocular surface anesthesia; and Zerviate (cetirizine ophthalmic solution 0.24%), a histamine-1 receptor antagonist for treatment of ocular itching related to allergic conjunctivitis.
“We are excited to partner with Harrow to provide access to an innovative branded line of ophthalmic products that complement our existing portfolio,” Allan Oberman, Apotex president and CEO, said in the release. “This alliance expands Apotex’s product offering in Canada to include innovative patented pharmaceutical medicines, aligned with our ongoing strategic focus to further expand our innovative branded pharmaceutical therapeutic areas of focus in becoming a Canadian-based global health company.”
Click Here to Manage Email Alerts